Biogen's Tecfidera was the Most Successful Drug Approved in 2013, But Other Mass. Biotechs Didn't Do So Well
A new report argues that Biogen’s blockbuster multiple sclerosis treatment Tecfidera was the biggest commercial success of roughly two dozen novel drugs approved in 2013, but other biotech firms in the Bay State didn’t fare quite as well.
In a study released on Wednesday, Waltham-based life science consulting firm Trinity Partners examined 22 novel drugs — those that represented a significant step forward in innovation — approved by the FDA in 2013. Trinity then ranked them based on commercial success, therapeutic success, and the cost and duration of research and development efforts. Not enough data was available to assess five other novel drugs approved in 2013.
In a study released on Wednesday, Waltham-based life science consulting firm Trinity Partners examined 22 novel drugs — those that represented a significant step forward in innovation — approved by the FDA in 2013. Trinity then ranked them based on commercial success, therapeutic success, and the cost and duration of research and development efforts. Not enough data was available to assess five other novel drugs approved in 2013.